ATE326243T1 - Methoden zur verbesserung der vaskularisierung und förderung der wundheilung - Google Patents

Methoden zur verbesserung der vaskularisierung und förderung der wundheilung

Info

Publication number
ATE326243T1
ATE326243T1 AT99935483T AT99935483T ATE326243T1 AT E326243 T1 ATE326243 T1 AT E326243T1 AT 99935483 T AT99935483 T AT 99935483T AT 99935483 T AT99935483 T AT 99935483T AT E326243 T1 ATE326243 T1 AT E326243T1
Authority
AT
Austria
Prior art keywords
arginine
methods
wound healing
promote wound
nitric oxide
Prior art date
Application number
AT99935483T
Other languages
English (en)
Inventor
Anton-Lewis Usala
Original Assignee
Encelle Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Encelle Inc filed Critical Encelle Inc
Application granted granted Critical
Publication of ATE326243T1 publication Critical patent/ATE326243T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02—Prostheses implantable into the body
    • A61F2/022—Artificial gland structures using bioreactors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
    • A61L27/222—Gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/26—Mixtures of macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3683—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix subjected to a specific treatment prior to implantation, e.g. decellularising, demineralising, grinding, cellular disruption/non-collagenous protein removal, anti-calcification, crosslinking, supercritical fluid extraction, enzyme treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/52—Hydrogels or hydrocolloids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/114—Nitric oxide, i.e. NO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/204—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with nitrogen-containing functional groups, e.g. aminoxides, nitriles, guanidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/21—Acids
    • A61L2300/214—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/41—Anti-inflammatory agents, e.g. NSAIDs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/432—Inhibitors, antagonists
    • A61L2300/434—Inhibitors, antagonists of enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/40—Preparation and treatment of biological tissue for implantation, e.g. decellularisation, cross-linking

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Transplantation (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Hematology (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99935483T 1998-07-10 1999-07-09 Methoden zur verbesserung der vaskularisierung und förderung der wundheilung ATE326243T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/113,437 US6231881B1 (en) 1992-02-24 1998-07-10 Medium and matrix for long-term proliferation of cells
US09/337,959 US6261587B1 (en) 1998-07-10 1999-06-22 Methods for increasing vascularization and promoting wound healing

Publications (1)

Publication Number Publication Date
ATE326243T1 true ATE326243T1 (de) 2006-06-15

Family

ID=22349408

Family Applications (2)

Application Number Title Priority Date Filing Date
AT99933792T ATE449619T1 (de) 1998-07-10 1999-07-09 Methode zur verminderung der immunerkennung
AT99935483T ATE326243T1 (de) 1998-07-10 1999-07-09 Methoden zur verbesserung der vaskularisierung und förderung der wundheilung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT99933792T ATE449619T1 (de) 1998-07-10 1999-07-09 Methode zur verminderung der immunerkennung

Country Status (9)

Country Link
US (5) US6231881B1 (de)
EP (1) EP1098959A2 (de)
JP (1) JP2002520013A (de)
AT (2) ATE449619T1 (de)
AU (1) AU758833B2 (de)
CA (1) CA2332701C (de)
DE (1) DE69941707D1 (de)
ES (1) ES2337320T3 (de)
WO (1) WO2000002999A2 (de)

Families Citing this family (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703017B1 (en) 1994-04-28 2004-03-09 Ixion Biotechnology, Inc. Reversal of insulin-dependent diabetes by islet-producing stem cells, islet progenitor cells and islet-like structures
US7070607B2 (en) * 1998-01-27 2006-07-04 The Regents Of The University Of California Bioabsorbable polymeric implants and a method of using the same to create occlusions
US6905707B2 (en) * 1998-05-28 2005-06-14 Medical Research Institute Controlled release arginine alpha ketoglutarate
EP1025861A1 (de) * 1999-02-04 2000-08-09 Roche Diagnostics GmbH Pharmazeutische Zusammensetzung von hydrophob modifizierten Hedgehog-Proteinen und deren Verwendung
US20050265977A1 (en) * 1999-04-30 2005-12-01 Elliott Robert B Xenotransplant for CNS therapy
US20090047325A1 (en) * 1999-04-30 2009-02-19 Neurotrophincell Pty. Limited Xenotransplant for cns therapy
AU4440000A (en) * 1999-04-30 2000-11-17 Diatranz Limited Xenotransplant for cns therapy
AU7382300A (en) * 1999-09-15 2001-04-17 Encelle, Inc. Method of preserving tissue viability during mechanical separation process
ATE341335T1 (de) * 2000-01-20 2006-10-15 Diabcell Pty Ltd Präparation und xenotransplantation von inseln aus schweinen
AU2001263495B2 (en) * 2000-05-31 2005-06-02 Encelle, Inc. Method of treating chronic ulcers
ES2386505T3 (es) * 2000-10-17 2012-08-22 Diatranz Otsuka Limited Preparación y xenotrasplante de islotes de cerdo
US20020188170A1 (en) * 2001-04-27 2002-12-12 Santamore William P. Prevention of myocardial infarction induced ventricular expansion and remodeling
US7494482B2 (en) * 2001-05-15 2009-02-24 The Brigham And Women's Hospital, Inc. Methods and apparatus for application of micro-mechanical forces to tissues
US20040097401A1 (en) * 2002-11-14 2004-05-20 Debatosh Datta Lysine in therapeutic angiogenesis, particularly in treating ischaemic conditions
US6702744B2 (en) 2001-06-20 2004-03-09 Advanced Cardiovascular Systems, Inc. Agents that stimulate therapeutic angiogenesis and techniques and devices that enable their delivery
US7156877B2 (en) 2001-06-29 2007-01-02 The Regents Of The University Of California Biodegradable/bioactive nucleus pulposus implant and method for treating degenerated intervertebral discs
US6790455B2 (en) * 2001-09-14 2004-09-14 The Research Foundation At State University Of New York Cell delivery system comprising a fibrous matrix and cells
US8608661B1 (en) 2001-11-30 2013-12-17 Advanced Cardiovascular Systems, Inc. Method for intravascular delivery of a treatment agent beyond a blood vessel wall
WO2003072157A1 (en) * 2002-02-21 2003-09-04 Encelle, Inc. Immobilized bioactive hydrogel matrices as surface coatings
US20080086792A1 (en) 2006-10-13 2008-04-17 Thomas Charles Kuracina Method and apparatus for diverting sweat, liquid, moisture or the like from an eye
US20030228287A1 (en) * 2002-06-07 2003-12-11 Regents Of The University Of California Maintenance of islet cells
US7361368B2 (en) 2002-06-28 2008-04-22 Advanced Cardiovascular Systems, Inc. Device and method for combining a treatment agent and a gel
AU2003261303B2 (en) * 2002-07-30 2008-07-10 Massachusetts Institute Of Technology Methods for perfusion and plating of primary hepatocytes and a medium therefore
EP1391284A1 (de) * 2002-08-23 2004-02-25 Kasai Kogyo Co., Ltd. Schichtverbund und dessen Herstellungsverfahren
US8383158B2 (en) 2003-04-15 2013-02-26 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
US8038991B1 (en) 2003-04-15 2011-10-18 Abbott Cardiovascular Systems Inc. High-viscosity hyaluronic acid compositions to treat myocardial conditions
US8821473B2 (en) 2003-04-15 2014-09-02 Abbott Cardiovascular Systems Inc. Methods and compositions to treat myocardial conditions
NZ581804A (en) * 2003-10-22 2011-10-28 Encelle Inc Bioactive hydrogel compositions for regenerating connective tissue
US20050245905A1 (en) * 2004-04-30 2005-11-03 Schmidt Steven P Local drug-delivery system
EP1773981A1 (de) * 2004-07-12 2007-04-18 Sorin Group Italia S.R.L. Vorrichtung und verfahren zur anzucht menschlicher zellen
US7784697B2 (en) 2004-12-23 2010-08-31 University Of Washington Methods of driving a scanning beam device to achieve high frame rates
US20060178696A1 (en) * 2005-02-04 2006-08-10 Porter Stephen C Macroporous materials for use in aneurysms
US9427496B2 (en) 2005-02-18 2016-08-30 Drexel University Method for creating an internal transport system within tissue scaffolds using computer-aided tissue engineering
US8187621B2 (en) 2005-04-19 2012-05-29 Advanced Cardiovascular Systems, Inc. Methods and compositions for treating post-myocardial infarction damage
US9539410B2 (en) 2005-04-19 2017-01-10 Abbott Cardiovascular Systems Inc. Methods and compositions for treating post-cardial infarction damage
US20080125745A1 (en) 2005-04-19 2008-05-29 Shubhayu Basu Methods and compositions for treating post-cardial infarction damage
US8828433B2 (en) 2005-04-19 2014-09-09 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US8303972B2 (en) 2005-04-19 2012-11-06 Advanced Cardiovascular Systems, Inc. Hydrogel bioscaffoldings and biomedical device coatings
US9942511B2 (en) 2005-10-31 2018-04-10 Invention Science Fund I, Llc Preservation/degradation of video/audio aspects of a data stream
NZ540597A (en) * 2005-06-08 2007-02-23 Neurotrophincell Pty Ltd A method for preventing the onset of type I diabetes comprising administering an implantable composition comprising living choroid plexus cells
EP1922052B1 (de) * 2005-08-08 2010-11-03 Angstrom Medica, Inc. Zementprodukte sowie verfahren zu deren herstellung und verwendung
DE102005054937A1 (de) * 2005-11-17 2007-05-24 Gelita Ag Angiogenese förderndes Substrat
CA2632257A1 (en) 2005-11-30 2008-05-02 Massachusetts Institute Of Technology Pathogen-detecting cell preservation systems
US20070231901A1 (en) * 2005-12-02 2007-10-04 Shuichi Takayama Microfluidic cell culture media
WO2007076505A2 (en) * 2005-12-28 2007-07-05 Essential Skincare, Llc Transferrin and transferrin-based compositions for diabetes treatment
US8999933B2 (en) * 2006-01-18 2015-04-07 Biolitec Pharma Marketing Ltd Photodynamic cosmetic procedure and healing method
US20090004159A1 (en) * 2006-01-24 2009-01-01 The Board Of Trustees Of The University Of Illinoi Polymerized Hemoglobin Media and Its Use in Isolation and Transplantation of Islet Cells
EP1978802A2 (de) * 2006-01-24 2008-10-15 Northfield Laboratories, Inc. Polymerisiertes hämoglobinmedium und verwendung davon bei der isolierung und transplantation von inselzellen
US7732190B2 (en) 2006-07-31 2010-06-08 Advanced Cardiovascular Systems, Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US9242005B1 (en) 2006-08-21 2016-01-26 Abbott Cardiovascular Systems Inc. Pro-healing agent formulation compositions, methods and treatments
US20080069855A1 (en) * 2006-08-21 2008-03-20 Bonutti Peter M Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss
EP2061873B1 (de) * 2006-09-21 2011-11-23 Tissue Genesis Zellfreisetzungsmatrizen
US9005672B2 (en) 2006-11-17 2015-04-14 Abbott Cardiovascular Systems Inc. Methods of modifying myocardial infarction expansion
US8741326B2 (en) 2006-11-17 2014-06-03 Abbott Cardiovascular Systems Inc. Modified two-component gelation systems, methods of use and methods of manufacture
US8192760B2 (en) 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
ES2968634T3 (es) * 2007-02-06 2024-05-13 Pioneer Surgical Tech Inc Dispositivos de implante intervertebral
CA2718573C (en) 2007-04-12 2020-07-14 The Brigham And Women's Hospital, Inc. Targeting abcb5 for cancer therapy
JP2010525873A (ja) 2007-05-01 2010-07-29 ザ ブライハム アンド ウイメンズ ホスピタル， インコーポレイテッド 創傷治癒デバイス
DE102007024239A1 (de) * 2007-05-16 2008-11-20 Gelita Ag Angiogenese förderndes Substrat
WO2009029734A2 (en) 2007-08-28 2009-03-05 Pioneer Surgical Technology, Inc. Cement products and methods of making and using the same
US20120301444A1 (en) * 2007-09-27 2012-11-29 Clarke Diana L Amnion-derived cell compositions, methods of making and uses thereof
US20090090214A1 (en) * 2007-10-04 2009-04-09 Chung Yuan Christian University Method for forming nano-scale metal particles
EP2222159B1 (de) * 2007-11-20 2018-02-21 Pioneer Surgical Orthobiologics, Inc. Kryokonservierung von zellen mittels vernetzten bioaktiven hydrogel matrixteilchen
EP2273952B1 (de) 2008-04-02 2018-02-21 Pioneer Surgical Technology, Inc. Bandscheibenimplantatvorrichtungen zur unterstützung der wirbel und vorrichtungen zu ihrer einführung
WO2009137074A1 (en) * 2008-05-06 2009-11-12 Indigene Pharmaceuticals, Inc. Compositions and methods for treating diabetic ulcers
HUE051328T2 (hu) 2009-08-28 2021-03-01 Sernova Corp Sejttranszplantációs módszerek és eszközök
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
WO2011057131A1 (en) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Polysaccharide based hydrogels
NZ603913A (en) * 2010-05-07 2015-09-25 Univ North Carolina Method of engrafting cells from solid tissues
WO2012048276A2 (en) 2010-10-08 2012-04-12 Caridianbct, Inc. Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
JP5808631B2 (ja) * 2011-09-29 2015-11-10 富士フイルム株式会社 血管新生用足場、及び再生医療用の血管の製造方法
US9132021B2 (en) 2011-10-07 2015-09-15 Pioneer Surgical Technology, Inc. Intervertebral implant
US9561247B2 (en) 2011-11-02 2017-02-07 Tif Management, Llc Methods and compositions for wound treatment
ES2559467T3 (es) 2011-12-23 2016-02-12 Pioneer Surgical Technology, Inc. Matriz continua con partículas osteoconductoras dispersadas en la misma, procedimiento de formación, y su uso para regenerar el hueso con la misma
EP2820428A1 (de) 2012-03-01 2015-01-07 3M Innovative Properties Company Verfahren zur förderung von wundheilung
US9101707B2 (en) 2012-04-27 2015-08-11 Gregory Zeltser Implantable bioartificial perfusion system
WO2014089472A1 (en) * 2012-12-07 2014-06-12 Kansas State University Research Foundation Peptide-albumin hydrogel properties and its applications
KR102474489B1 (ko) 2013-02-19 2022-12-06 칠드런'즈 메디컬 센터 코포레이션 안구 질환을 치료하기 위한 abcb5(+) 줄기 세포
CN105517587B (zh) 2013-05-10 2019-02-19 儿童医学中心公司 伤口愈合与组织工程
JP5747184B2 (ja) * 2013-06-28 2015-07-08 株式会社日本生物製剤 肝細胞増殖剤
CN105992816B (zh) 2013-11-16 2018-04-17 泰尔茂比司特公司 生物反应器中的细胞扩增
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
WO2016049421A1 (en) 2014-09-26 2016-03-31 Terumo Bct, Inc. Scheduled feed
HK1249108A1 (zh) 2015-01-20 2018-10-26 米拉根医疗股份有限公司 Mir-92抑制剂及其用途
EP3288556A4 (de) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Oral zerfallende zusammensetzungen
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
CN109415696A (zh) 2016-05-25 2019-03-01 泰尔茂比司特公司 细胞扩增
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
TWI670371B (zh) 2016-10-04 2019-09-01 全崴生技股份有限公司 用於細胞冷凍保存的組成物和方法
EP3656841A1 (de) 2017-03-31 2020-05-27 Terumo BCT, Inc. Zellexpansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
WO2019021143A1 (en) * 2017-07-22 2019-01-31 Rangasamy Naidu Educational Trust HYDROGEL BASED ON L-HISTIDINE MOLECULES
CA3074834C (en) 2017-09-08 2025-09-16 Xtant Medical Holdings, Inc. INTERVERTEBRAL IMPLANTS, INSTRUMENTS AND PROCESSES
USD907771S1 (en) 2017-10-09 2021-01-12 Pioneer Surgical Technology, Inc. Intervertebral implant
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4477567A (en) 1977-12-01 1984-10-16 Connaught Laboratories Limited Continuous bovine beta cell line
US4198479A (en) 1979-03-30 1980-04-15 Merck & Co., Inc. Replacement of animal serum proteins by human albumin for growth and interferon production by Namalva cells
US4520821A (en) 1982-04-30 1985-06-04 The Regents Of The University Of California Growing of long-term biological tissue correction structures in vivo
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US5132223A (en) 1983-11-10 1992-07-21 Thomas Jefferson University Process and medium for cloning and long-term serial cultivation of adult human endothelial cells
US4868121A (en) 1985-02-07 1989-09-19 Mcdonnell Douglas Corporation Islet isolation process
US4978616A (en) 1985-02-28 1990-12-18 Verax Corporation Fluidized cell cultivation process
NO166836C (no) * 1985-03-14 1991-09-11 Univ California Fremgangsmaate for behandling av et organtransplantat.
US4863856A (en) 1985-04-04 1989-09-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive materials
US4997753A (en) 1985-04-04 1991-03-05 Verax Corporation Weighted collagen microsponge for immobilizing bioactive material
US5100783A (en) 1985-05-10 1992-03-31 Verax Corporation Weighted microsponge for immobilizing bioactive material
AU589438B2 (en) 1985-08-26 1989-10-12 Hana Biologics, Inc. Transplantable artificial tissue and process
US4902295A (en) 1985-08-26 1990-02-20 Hana Biologics, Inc. Transplantable artificial tissue
GB8604497D0 (en) 1986-02-24 1986-04-03 Connaught Lab Separation of islets of langerhans
FR2600076A1 (fr) 1986-06-12 1987-12-18 Fond Ctre Nal Transfusion Milieu de culture comportant de l'albumine humaine, procede de preparation d'un produit injectable a partir de ce milieu, produit obtenu et son utilisation, composition obtenue
US5079160A (en) 1987-06-08 1992-01-07 Lacy Paul E Method to isolate clusters of cell subtypes from organs
US5457093A (en) * 1987-09-18 1995-10-10 Ethicon, Inc. Gel formulations containing growth factors
AU632273B2 (en) * 1988-03-09 1992-12-24 Terumo Kabushiki Kaisha Medical material permitting cells to enter thereinto and artificial skin
US4950483A (en) 1988-06-30 1990-08-21 Collagen Corporation Collagen wound healing matrices and process for their production
EP0363125A3 (de) 1988-10-03 1990-08-16 Hana Biologics Inc. Produkt, enthaltend vermehrungsfähige Bauchspeicheldrüsen-Endokrinezellen, und Verfahren
US4957902A (en) * 1988-12-20 1990-09-18 Board Of Regents, The University Of Texas System Peptide inhibitors of wound contraction
US5196185A (en) * 1989-09-11 1993-03-23 Micro-Collagen Pharmaceutics, Ltd. Collagen-based wound dressing and method for applying same
WO1991009119A1 (en) 1989-12-13 1991-06-27 Trancel Corporation Improved alginate microcapsules, methods of making and using same
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
US5336616A (en) 1990-09-12 1994-08-09 Lifecell Corporation Method for processing and preserving collagen-based tissues for transplantation
GB9022545D0 (en) 1990-10-17 1990-11-28 Wellcome Found Culture medium
US5192312A (en) 1991-03-05 1993-03-09 Colorado State University Research Foundation Treated tissue for implantation and methods of treatment and use
SG47470A1 (en) 1991-04-25 1998-04-17 Univ Brown Res Found Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
WO1993000441A1 (en) 1991-06-24 1993-01-07 Pacific Biomedical Research, Inc. Hormone-secreting cells maintained in long-term culture
CA2071137A1 (en) 1991-07-10 1993-01-11 Clarence C. Lee Composition and method for revitalizing scar tissue
US5116753A (en) 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
US5591709A (en) * 1991-08-30 1997-01-07 Life Medical Sciences, Inc. Compositions and methods for treating wounds
WO1994015589A1 (en) 1992-12-30 1994-07-21 Clover Consolidated, Limited Cytoprotective, biocompatible, retrievable macrocapsule containment systems for biologically active materials
US5824331A (en) 1992-02-24 1998-10-20 Encelle, Inc. Bioartificial devices and cellular matrices therefor
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
WO1993016685A1 (en) 1992-02-24 1993-09-02 Encelle, Inc. Bioartificial endocrine device
US5830492A (en) 1992-02-24 1998-11-03 Encelle, Inc. Bioartificial devices and cellular matrices therefor
ATE204470T1 (de) 1992-05-29 2001-09-15 Vivorx Inc Mikroverkapselung von zellen
EP0655910A4 (de) 1992-07-29 1996-02-28 Univ Washington Verwendung eines beutels zur implantation von lebenden zellen.
US5262055A (en) 1992-10-19 1993-11-16 The University Of Utah Implantable and refillable biohybrid artificial pancreas
DE4431598C2 (de) 1993-03-03 1997-03-20 Michael Sittinger Verfahren zum Herstellen eines Implantates aus Zellkulturen
US5405772A (en) 1993-06-18 1995-04-11 Amgen Inc. Medium for long-term proliferation and development of cells
AU692506B2 (en) 1993-11-17 1998-06-11 Ibah, Inc. Transparent liquid for encapsulated drug delivery
NZ329619A (en) 1994-01-13 1999-09-29 Rogosin Inst Use of macroencapsulated secretory cells in agarose coated collagen gel material to treat diseases related to secretory cell failure
US5512477A (en) 1994-04-21 1996-04-30 Genzyme Corporation Serum-free medium supplement
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5840059A (en) 1995-06-07 1998-11-24 Cardiogenesis Corporation Therapeutic and diagnostic agent delivery
WO1997002569A1 (en) 1995-07-03 1997-01-23 Autronic Plastics, Inc. Package and storage unit for digital information storage media
US5681587A (en) 1995-10-06 1997-10-28 Desmos, Inc. Growth of adult pancreatic islet cells
US5672361A (en) 1996-03-29 1997-09-30 Desmos, Inc. Laminin 5 for growth of pancreatic islet cells
CA2179341A1 (en) 1996-04-12 1997-10-13 Gregory S. Korbutt Methods for isolating, enriching and increasing the maturation of cells
WO1998004681A2 (en) 1996-07-25 1998-02-05 Genzyme Corporation Chondrocyte media formulations and culture procedures
ATE356198T1 (de) 1996-10-11 2007-03-15 Invitrogen Corp Definierte systeme zur kultivieurng epithelialer zellen und anwendung derselben

Also Published As

Publication number Publication date
US6231881B1 (en) 2001-05-15
WO2000002999A2 (en) 2000-01-20
US6261587B1 (en) 2001-07-17
WO2000002999A3 (en) 2000-04-20
ES2337320T3 (es) 2010-04-22
DE69941707D1 (de) 2010-01-07
CA2332701A1 (en) 2000-01-20
US20010010826A1 (en) 2001-08-02
EP1098959A2 (de) 2001-05-16
US20010019841A1 (en) 2001-09-06
AU4977299A (en) 2000-02-01
US6730315B2 (en) 2004-05-04
JP2002520013A (ja) 2002-07-09
AU758833B2 (en) 2003-04-03
US6315994B2 (en) 2001-11-13
ATE449619T1 (de) 2009-12-15
CA2332701C (en) 2010-04-20
US20010007658A1 (en) 2001-07-12
US6713079B2 (en) 2004-03-30

Similar Documents

Publication Publication Date Title
ATE326243T1 (de) Methoden zur verbesserung der vaskularisierung und förderung der wundheilung
DE69635940D1 (de) Hydrogelmatrix für Zellgewebelagerung
CA2410965A1 (en) Method of stimulating hair growth
BR9807290A (pt) Artigo biocompatìvel e processo para preparar o mesmo
RU2008136324A (ru) Желудочно-кишечный пролиферативный фактор и его применения
ATE309775T1 (de) Die verwendung von prostaglandin f analoga zur herstellung von zusammensetzungen für die behandlung von haarausfall.
DK1545587T3 (da) Lactoferrinsammensætninger og fremgangsmåder til behandling af diabetiske sår
DE60139457D1 (de) Ungen unter verwendung einer geweberisikokarte
NZ507050A (en) Benzamide and sulfonamide substituted aminoguanidines and alkoxyguanidines as protease inhibitors
TR201900937T4 (tr) Organların ve dokuların muhafaza edilmesine yönelik yöntem.
DE69834136D1 (de) Gefrierschutzprotein
ATE324880T1 (de) Behandlung von mastalgie mit4-hydroxy-tamoxifen
DE60227670D1 (de) Aminosäuren-enthaltende zusammensetzungen, geeignet zur wundheilung, insbesondere zur behandlung des auges
AU2002330555A1 (en) Cosmetic or dermatological use of peptides for promoting adhesion between skin cells
CA2337051A1 (en) Methods for increasing vascularization and promoting wound healing
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
DE50105373D1 (de) Dipeptidische hemmstoffe für den gerinnungsfaktor xa
ES2421407T3 (es) Agente y composición para la curación de heridas
PT1296675E (pt) Composicoes a base de aminoacidos apropriadas para o tratamento da insuficienciacardiaca
JPS56103106A (en) Protective agent of hair for permanent wave
ATE299028T1 (de) Behandlung von krebserkrankungen mit aplidin in kombination mit carnitin oder acetylcarnitin
DK0793503T3 (da) Anvendelse af hepatocyt-vækstfaktor til inducering af profilerering og differentiering af hemotopoietiske celler
DE60230506D1 (de) Topische behandlungen mit alkanolaminen
Sakai et al. Sodium sulfite and N-acetylcysteine: new additives to dialysate for inhibiting formation of glucose degradation products and advanced glycation end-products
DE602004026838D1 (de) Eine metacaspasen-klasse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties